Kav, T. Et Al. 2017. Azelnidipine, a novel calcium channel blocker, ameliorates severity of colitis in DSS induced colitis in mice possibly by modulating tissue levels of TNF-alpha and IL-6. JOURNAL OF CROHNS & COLITIS , vol.11 .

Kav, T., AKYOL, A., Aksoy, E., Ozer, C., Torgutalp, M., & Sivri, B., (2017). Azelnidipine, a novel calcium channel blocker, ameliorates severity of colitis in DSS induced colitis in mice possibly by modulating tissue levels of TNF-alpha and IL-6. JOURNAL OF CROHNS & COLITIS , vol.11.

Kav, T. Et Al. "Azelnidipine, a novel calcium channel blocker, ameliorates severity of colitis in DSS induced colitis in mice possibly by modulating tissue levels of TNF-alpha and IL-6," JOURNAL OF CROHNS & COLITIS , vol.11, 2017

Kav, T. Et Al. "Azelnidipine, a novel calcium channel blocker, ameliorates severity of colitis in DSS induced colitis in mice possibly by modulating tissue levels of TNF-alpha and IL-6." JOURNAL OF CROHNS & COLITIS , vol.11, 2017

Kav, T. Et Al. (2017) . "Azelnidipine, a novel calcium channel blocker, ameliorates severity of colitis in DSS induced colitis in mice possibly by modulating tissue levels of TNF-alpha and IL-6." JOURNAL OF CROHNS & COLITIS , vol.11.

@article{article, author={T. Kav Et Al. }, title={Azelnidipine, a novel calcium channel blocker, ameliorates severity of colitis in DSS induced colitis in mice possibly by modulating tissue levels of TNF-alpha and IL-6}, journal={JOURNAL OF CROHNS & COLITIS}, year=2017}